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Abstract
We report a new theranostic device based on lead sulfide quantumdots (PbSQDs)with optical
emission in the near infraredwavelength range decoratedwith affibodies (small 6.5 kDa protein-based
antibody replacements) specific to the cancer biomarker human epidermal growth factor receptor 2
(HER2), and zinc(II) protoporphyrin IX (ZnPP) to combine imaging, targeting and therapywithin
one nanostructure. Colloidal PbSQDswere synthesized in aqueous solutionwith a nanocrystal
diameter of∼5 nmand photoluminescence emission in the near infraredwavelength range. The
ZHER2:432 affibody,mutated through the introduction of two cysteine residues at the C-terminus
(Afb2C), was used as capping ligand to formAfb2C-PbSQDs that have a high binding affinity for
HER2, which is overexpressed in several types of cancer including breast cancer. Afb2C-PbSQDswere
furthermodified by conjugationwith ZnPP, which acts as an anticancer agent. The biological activity
of theseQDswas tested against SKBR3 (HER2-positive) andMDA-MB-231 (HER2-normal) breast
cancer cells, with results showing that ZnPP-Afb2C-functionalized PbSQDswere successfully
targeted to theHER2-overexpressing cancer cells and induced cell apoptosis thanks to the conjugation
with ZnPP. These results expand the use of theQDnanoplatformwith the formulation of novel
nanomaterials for targeted delivery and combined imaging and therapy via direct surface-protein
interaction.
Introduction
The development of theranostic agents for simultaneous disease detection and targeted therapy has attracted
considerable attention in recent years and brought significant advances to cancer treatments [1, 2]. This has been
achieved by using drug delivery vehicles, such as polymer-based nanoparticles [3], protein nanocages [4], or
liposomes, to encapsulate imaging and therapeutic agents, and also by direct attachment of ligands to the surface
of solid colloidal nanoparticles (e.g. semiconductor quantumdots (QDs), silver, gold or iron oxide
nanoparticles) [5–7]. In particular, the use of semiconductorQDs offers the benefit of tunable optical emission
[8]with in vivo imaging potential in the near-infrared (NIR)wavelength rangewhere absorption of biological
tissues is low. This is offered byQDs based on IV-VI group elements (PbS, PbSe) [9–13]. One of the areas where
NIR-emitting nanomaterials are currently being investigated for detection and treatment is the targeting of
breast cancers [14, 15], exploiting the elevated expression of estrogen receptor alpha (ERα) and/or epidermal
growth factor receptor 2 (HER2). Currently, focus has shifted towardsHER2-based detection and therapy as this
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cancers, while not expressed in immunohistochemically detectable quantities in normal adult tissue cells. HER2
overexpression is associatedwith poor prognosis in the absence of systemic therapy [16].
To date,molecules that have been explored for breast cancer-specific targeting include naturally recognized
protein capsules, such as ferritin, and immunoglobulinG (IgG) antibodies [17–19]. A promising alternative are
affibodies (Afb), which can replace antibodies as the targeting functionality of biopharmaceuticals for diagnostic
and therapeutic applications [20, 21]. The ZHER2:432 Afb is a non-immunoglobulin-based, highly specific
binding protein of small size (58 amino acids,∼6.5 kDa), engineered from a 3-helix bundle Z derived from
staphylococcal protein A,with a high binding affinity forHER2 (KD∼22 pM) [22, 23]. It is known for fast and
reversible folding, high solubility in aqueous solutions, an attachment surface as large as an antibody antigen
binding pocket and for being easily expressed in high yields inE. coli, thusmaking it an ideal targeting agent for
cancer therapies [24–26], which is slowlymaking its way in theranostic applications [27]. The immobilization of
Afb’s was recently demonstrated on nanoparticles, including Ag2S and InAs/InP/ZnSe core/shell/shell QDs
through the use of a heterobifunctional linker conjugation on PEG-cappedQD surfaces, or via electrostatic
interactions [28–30], but no direct surface attachment has been reported to date.
Current breast cancer therapy comprises several partially successful drugs; however, new therapeutic
strategies are needed, especially formetastatic and drug-resistant breast cancers [31, 32]. Recently, the
therapeutic anticancer activity of zinc(II) protoporphyrin IX (ZnPP)was demonstratedwith the inhibition of
hemeoxygenase-1 [33, 34], an enzymewhich is highly overexpressed in cancerous tissues and exerts a
cytoprotective effect by neutralizing oxidative stress in cells [35]. At the same time, ZnPP can also induce cell
apoptosis by generating singlet oxygen species upon irradiationwith blue light (λex=425 nm), allowing for
applications in cancer photodynamic therapy [36–39]. Despite the number of promising advances, including
nano-engineering of drug delivery systems [40] as well as surface decoration ofQDs [41] combined targeting,
anticancer activity and imagingwithin one nano-construct is yet to be achieved. Facile procedures for the
controllable and direct attachment of targeting and therapeutic agents onto theQDs surface still remain
challenging.
In this workwe describe a one-pot synthesis of water-soluble and biocompatible near-infrared-emitting PbS
QDs functionalizedwithAfb andZnPP for diagnosis and therapy (figure 1(a)). The simultaneous attachment of
both ZHER2:432 Afb andZnPPmolecules onto aQD surface will produce a novel theranostic agent that combines
the benefits of selective targeting and specific cellular uptake induced byAfb, theNIR fluorescent bioimaging of
QDs and the anticancer activity of ZnPP. The ZHER2:432 Afbwas geneticallymodified to introduce two specific
mutations to incorporate two cysteine residues at its C-terminus—G82C and S83C. TheAfb2C generatedwith
two thiol groups allows for a bidentate interaction of the proteinwith theQD and consequently stronger binding
to theQD surface, hence increasing the long-term stability of theQD-protein conjugate [39]. Afb2C-PbSQDs
were furthermodified by conjugating ZnPP at the lysine residues of Afb2C to produce ZnPP-Afb2C-PbSQDs,
whichwere found to be stable in solution and optically active in theNIR. The effect of theseQDs onHER2-
overexpressing (HER2+) SKBR3 cells was explored to confirm selectivity and activity and is reported herein.
The approach reported here for the synthesis of novel nanocomposites that combine in one structure targeting,
imaging and therapy is relevant for the advancement of theranostics into the clinic.
Results and discussion
Site-directedmutagenesis was performed to create a specific change on the ZHER2:342 affibody (Afb)DNA
sequence. In the pJexpress401 plasmid, theAfb2C genewas designedwith anN-terminalHis-tag, and two
mutations (G82C and S83C)whichwere introduced at its C-terminus; we note that these residues were not
critical for the Afb binding toHER2 (Supplementary Information, SI1). Themutant Afb2Cproteinwas
successfully expressed in BL21 (DE3)E. coli and purified using nickel(II)-immobilizedmetal affinity
chromatography (IMAC) followed by further purification by size exclusion chromatography (SEC). The
presence and purity of the Afb2C proteinwere confirmed by SDS-PAGE. To examine the stability of the Afb2C
structure under the conditions used forQD synthesis, the secondary structure of theAfb2C proteinwas
determined at pH7.0 and pH11.0 using circular dichroism (CD) spectroscopy (see Supplementary Information,
Figure S2), indicating that theα-helical secondary structure of the Afb2C found at pH7.0was retained at
pH11.0.
TheAfb2Cwas used as the capping ligand in a one-pot synthesis of PbSQDs. TheQDswere synthesized in
aqueous solution followingmodified procedure reported in [11, 13]withmolar ratio of Pb:S=1:0.3
(figure 1(a)). In this process, the presence of two cysteine sites in Afb2Coffers bidentate interactionwith theQD
surface and greater stability, as was previously demonstrated for other bidentate ligands such as dihydrolipoic
acid [42]. Then, ZnPPwas conjugated in situ to Afb2C-PbSQDs by reacting the lysine residues locatedwithin the
Afb2Cproteinwith theNHS-activated carboxyl groups on the protoporphyrin, forming a stable amide bond—
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wedid not investigate further which lysines had been involved in the process. Figure 1(b) shows the native
agarose gel electrophoresis spots of Afb2C-PbSQDs and the ZnPP-Afb2C-PbSQDs.Under illuminationwith
UV light (λ= 300–400 nm), nofluorescent bandswere observed on native PAGE gels of Afb2C-PbSQDs as
these emit in theNIR region, while clear red fluorescence was observed for ZnPP-Afb2C-PbSQDs, as expected
from the presence of ZnPP, confirming successful conjugation (figure 1(b)).We also explain the lowermigration
spot for ZnPP-Afb2C-PbSQDswith their fastermigration compared toAfb2C-PbSQDs, due the change in net
charge (pI) derived from the neutralization of lysine residues after conjugation, despite their overall larger size.
The synthesizedQDs have room temperature photoluminescence (PL) centered atλPL∼1180 nm
(figure 1(d)), similar to that expected from this synthesismethodwith thioglycerol/dithioglycerol capping
ligands, and suggest that theAfb2C can be used instead of dithioglycerol to provide efficient passivation of the
QD surface. Significantly, attachment of ZnPP does not affect the optical properties of theQDs [11, 43].We note
that the presence of bothAfb2C andZnPP on theQD surface providesmore efficient surface passivation and
greater stability againstOstwald ripening, compared toAfb2Conly passivatedQDs. BothQD solutions have
comparable PL peak position for the fully ripened samples (figure 1(d)). The TEM images revealed that the PbS
QDs had a spherical shape, high crystallinity and an average diameter of 5±1 nm (figure 1(c) and
Supplementary Information, figures S3, S4), with the observed size comparable to that estimated from the PL
peak position usingmodel developed byMoreels et al [44]. BothAfb2C-PbSQDs andZnPP-Afb2C-PbS have
long term colloidal stability with respect tomorphological and optical properties over a period of at least three
months (stored under nitrogen atT=4 °C).
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assaywas used to study the
growth inhibitory effects of Afb2C-PbSQDs andZnPP-Afb2C-PbSQDs in SKBR3 andMDA-MB-231 cell lines.
SKBR3 is a human breast cancer cell line expressing between 1,000,000 and 2,000,000HER2 per cell, whereas
non-cancerous cells display∼20,000HER2 per cell [45, 46]. Consequently, the SKBR3 cell line is used as a
positive control inHER2 assays and is considered a suitable preclinicalmodel for screening therapies that target
Figure 1. (a)A cartoon of the formation of ZnPP-Afb2C-PbSQDs. (b)Anative agarose gel electrophoresis of Afb2C-PbS andZnPP-
Afb2C-PbSQDs; (right) the gel underUV light (λex= 300–400 nm) and (left) gel under visible light. The agarose gel was preparedwith
a low percentage agarose (0.5%w/v), and the samples were electrophoresed at 100V for 1 h. (c)A representativeHRTEM image of
Afb2C-PbSQDs. (d)Room temperature PL spectra of PbSQDs cappedwith Afb2C (red) andwith ZnPP-Afb2C (black) for freshly
prepared samples (continuous line) and followingfiveweeks of storage at 4 °C (dashed line).
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HER2 [45, 46]. Clinically, HER2+breast cancers develop resistance to trastuzumab (Herceptin®), a therapeutic
antibody developed to target and treat this type of breast [32].MDA-MB-231 triple negative breast cancer
(TNBC) cells, instead, display∼100-fold lowerHER2. Also lacking estrogen and progesterone receptors, TNBCs
are associatedwith poor prognosis, exhibiting highly invasive characteristics [47, 48]. Following 72 h exposure,
dose-dependent growth inhibitionwas observed in SKBR3 cells in the presence of Afb2C-PbSQDs, with amean
GI50 value of 26μgml
−1 (Afb2C concentration 4.5mgml−1 during synthesis), which is significantly lower than
that observed for Afb2C alone andZnPP alone (GI50>100μgml
−1,figure 2 and Supplementary Information,
figure S5) [37]; no growth inhibitory effects were observed inMDA-MB-231 cells<100μgml−1 (figure 2 and
Supplementary Information, figure S5). These results suggest that the Afb2C is recognized byHER2 receptors as
predicted and leads to selective and enhanced uptake of the nanoplatform in theHER2+SKBR3 cells. In this
case the activity is due to the presence of PbSQDs, which have been shownpreviously to be non-toxic to normal
cells (MRC-5) but to induce cytotoxic effects in cancerous cells [11]. Comparable results are observed following
exposure to ZnPP-Afb2C-PbSQDs (figure 2 and Supplementary Information, figure S6). The lowerGI50 value
in SKBR3 cells confirmsAfb-induced targeting.We note that the greater growth inhibition observed inMDA-
MB-231 exposed toZnPP-Afb2C-PbS, compared toAfb2C-PbS only, is likely due to extracellular activity of
ZnPP conjugated on our nanoplatform, as this is able to generate ROS and inhibit hemeoxygenase-1 and acts as
photosensitizer [34, 37, 38]. It was shownpreviously that the anticancer activity of ZnPP is different in different
cell lines and can be enhanced, e.g. by pre-treatment of cancer cells with agents affecting protein
transportation [39].
To investigate further the nature of growth inhibitory activity, we performed cell cycle studies in SKBR3
cells. SKBR3 cells were exposed toAfb2C-PbSQDs or ZnPP-Afb2C-PbSQDs at a concentration of 2×GI50
value for 24 h, 48 h, and 72 h. Theflow cytometry results (figures 3(a) and S7) revealed increasing populations in
the pre-G1 phase with increasing exposure time. For Afb2C-PbSQDs the pre-G1 population increased from
13.3% after 24 h to 52.3% (P<0.0001) after 72 h of treatment, andwas accompanied by decreasedG1, S and
G2/Mevents (figure 3(b)). Similar changes were observed for ZnPP-Afb2C-PbSQDs, where the cell population
in pre-G1 phase increased from18.9% to 52.8% after 72 h treatment (figure 3(b)). The presence of significant
pre-G1 events is indicative ofDNAdegradation and consequent cell apoptosis, previously reported following
cancer cell exposure to PbSQDs [11]. Resistance to apoptosis is a hallmark of human cancer [49], thwarting
Figure 2.Results of theMTT assays for (a)MDA-MB-231 and (b) SKBR3 cells following 72 h treatmentwith Afb2C alone, Afb2C-PbS
QDs andZnPP-Afb2C-PbSQDs. n=6; experiments were repeated 3 times, and all data point are showwith standard deviation.
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successful treatment; therefore, inducing apoptosis in cancer cells is amajor goal of anticancer therapies.We
expected that ZnPP-Afb2C-PbSQDswould exhibit augmented anti-proliferative effects due to conjugationwith
ZnPP, however, Afb2C-PbSQDs andZnPP-Afb2C-PbSQDs had similar effects on the SKBR3 cell cycle. Our
results suggest that conjugation of ZnPPwithAfb2C-PbSQDs decreases the affinity of Afb forHER2 receptors
and consequently reduces the effects of ZnPP-Afb2C-PbSQDs onHER2+SKBR3 cells. The reduced dose of
ZnPP-Afb2C-PbSQDs in these cells is therefore responsible for their similar growth inhibitory effect to Afb2C-
PbSQDs.
Further flow cytometric studies were performed to investigate themechanismof cell death, using dual
propidium iodide (PI) and annexinV staining of cells. The results confirmed cell death by apoptosis (early- and
late-stage) for Afb2C-PbSQDs and late-stage apoptosis-detection for ZnPP-Afb2C-PbSQDs following
exposure to 2×GI50 for 24 h, 48 h and 72 h,where apoptotic populations gradually increasedwith time to
>20% (Supplementary Information, SI2). Afb2C-PbSQDs induced late apoptosis in SKBR3 cells after 24 h of
treatment and their effect increased by 44%after 72 h. In addition, SKBR3 cell necrosis was also detected after 72
h of treatment: we conclude that Afb2C-PbSQDs induced SKBR3 cell apoptosis and necrosis, themajor cell
death pathways. For ZnPP-Afb2C-PbSQDs, cells underwent necrosis after 24 h of exposure, doubling to 23.1%
after 72 h of treatment (supplementary information SI2,figure S11 (available online at stacks.iop.org/NANOX/
2/040005/mmedia)). This indicates that the nanocomposites have a potent anti-proliferative effect on SKBR3
cells and that they forcemost cells to undergo necrosis bypassing programmed cell death: we conclude that
conjugation of ZnPPwith Afb2C-PbSQDs switches SKBR3 cell fate from apoptosis to necrosis, suggesting a
sudden catastrophic cytotoxic effect for this nanocomposite compared toAfb2C-PbSQDs.
The ability of ZnPP-Afb2C-PbSQDs to enter and localize in cells wasmonitored using flow cytometry in
SKBR3 andMDA-MB-231. Cells were incubatedwith ZnPP-Afb2C-PbSQDs at 2×GI50 for 3 h. The uptake of
Figure 3.Cell cycle analysis for SKBR3 cells. SKBR3 cells were seeded at a density of 7.5×104 cells/well in 6-well plates and incubated
for 24 h before treatment with either Afb2C-PbSQDs andZnPP-Afb2C-PbSQDs at 2xGI50 for 24 h, 48 h, and 72 h.
* indicates
significant difference compared to control ** (P<0.1), ***(P<0.001) and ****(P<0.0001). n=2; experiments were repeated 3
times. (a)Histograms show the time-dependent response of control (untreated) cells and 24 h, 48 h, and 72 h exposure toAfb2C-PbS
QDs. (b)Programmed cell death analysis of SKBR3 cells following exposure to Afb2C-PbSQDs andZnPP-Afb2C-PbSQDs.
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ZnPP-Afb2C-PbSQDswas∼2-times higher inHER-2+SKBR3 cells compared toMDA-MB-231 cells
(Supplementary Information, SI3).
Confocalmicroscopy imagingwas used to detect intracellular fluorescence of ZnPP-Afb2C-PbSQDs
(λem=593 nm, excitationwith 425 nm,figure 4 and supplementary information, SI3) and indicated that the
agent is distributed in the cell cytoplasm; the non-uniform fluorescencewith small brighter areas suggests
uptake by endocytosis. Despite reporting significant agent uptake, no detectablefluorescencewasmeasured in
MDA-MB-231 cells by confocalmicroscopy (supplementary information, figure S13): we explain this fact with
the presence of ZnPP that leads to cell death, as reported previously [37], a consequence of highmetabolic
turnover and genetic instability,making cellsmore susceptible to ROS generation and its consequences.
Confocal images also revealed changes inmorphology of both studied cell lines following treatment with ZnPP-
Afb2C-PbSQDs, such as blebbing of the cellmembrane, which is associatedwith late-stage apoptosis and
necrosis; that this has occurred is strongly indicated by intracellular PI accumulation observed inflow
cytometric assays, and corroborates an apoptoticmechanismof cell death.
In our recent work, we demonstrated deep tissue imagingwith near-infrared PbSQDs [13]. The results in
the present report on novel PbSQDs directly coatedwith the anti-HER2Afb2Cprotein and conjugatedwith
ZnPP indicate realistic prospects for their utilization in cancer imaging and therapy. The enhanced uptake
demonstrated for Afb2C-functionalized nanoparticles is of benefit for drug delivery and imaging ofHER2-
overexpressing cancer cells [50].With the present report, we have also demonstrated the possibility of using the
QDs’ surface for the direct incorporation of other active principles within the same nanostructure for
theranostic applications, which could be expanded to other agents, e.g. the therapeutic antibodies pertuzumab
and trastuzumab [50].
In conclusion, we have produced stable near-infrared colloidal PbSQDs directly passivatedwith a small
proteinAfb2C and further functionalizedwith ZnPP. TheAfb2Cprovides targeting to theHER2+cells while
ZnPP contributed therapeutic activity against breast cancer cells. The novel theranostic ZnPP-Afb2C-PbSQDs
demonstrated selective anticancer activity, targetingHER2+cells and triggering apoptotic cell death; the
bioimaging application has also been reported in vitro, and further studies are required to assess the activity of
theseQDs in vivo and to explore their theranostic potential.
Materials andmethods
DNAmutagenesis
DNA sequence gene encodingAfb in pJexpress401 plasmidwasmutated by replacing glycine and serine at
positions 82 and 84 respectively with cysteine usingQ5® Site-DirectedMutagenesis according to the
manufacturer’s instructions (NewEnglandBiolabs) to produce Afb2C. Afb2C in pJexpress401 plasmidwas
Figure 4.Confocal images. (a) IThe brightfield view and (b) the fluorescence emitted fromSKBR3 cells after exposure to ZnPP-
Afb2C-PbSQDs for 3 h. (c)The brightfield and (d) thefluorescence images of untreated SKBR3 cells. Cells were seeded at a density of
10×103 cells/well in 8-well plate and treatedwith ZnPP-Afb2C-PbSQDs at 2×GI50. For both experiments, ZnPPwas excited at
425 nmand the emitted light was detected at 594 nm.
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amplified by transforming in theDH5α calcium competent cells and then the plasmidwas extracted and
purified using theWizard Plus® SVMiniprep kit (Promega).
Afb2C expression and purification
For the Afb2C expression, isopropylβ-D-1-thiogalactopyranoside (IPTG) (1mM, Fisher Scientific)was added
for 4 h atT=37 °C into E. coliBL21 (DE3) culture containing the pJexpress401:Afb2C plasmid. The Luria
Bertani (LB)medium supplementedwith kanamycin (50μgml−1, Apollo Scientific)was used. Cells were
collected by centrifugation (2500 g, 25 min,T=4 °C), resuspended in binding buffer (40ml of 20mMTris
pH8.3 (Fisher Scientific), 10mM imidazole (SigmaAldrich)), 1mMphenylmethyl sulfoxide (PMSF) (Sigma
Aldrich)) and sonication. The samplewas then centrifugation (35000 g, 25 min,T=4 °C) and the supernatant
was loaded on a 5ml nickel column (GEHealthcare). 5ml of binding buffer (20mMof Tris pH8.6, 10mMof
imidazole)was used for washing; washingwas repeated 3-times. Afb2Cwas then eluted using a linear gradient of
increasing imidazole concentration up to 500mM.The purifiedAfb2Cwas loaded into 6–8KMWCOdialysis
tubing (SpectrumLaboratories) and dialyzed against two changes of Tris buffer (2 l, 20mMTris pH8.3, 1mM
DTT) for∼16 h. Tricine-SDS-gel electrophoresis was used to confirmpresence of Afb2C. All fractions
containing Afb2Cwere loaded on a size exclusion column (Superdex 75 10/300GL) andwere analyzed using
Tricine-SDS-PAGE.NANODropA-1000 spectrophotometer was used tomeasure the absorbance of the
samples (extinction coefficient=8,480Mcm−1), whichwere used to calculated the concentration of Afb2C.
The yield of purified proteinwas 4mg per L of culture.
MALDI-TOFMS
BrukerMatrix Assisted LaserDesorption/Ionization (MALDI-TOF, BrukerUltraflex III)MSwas used to
analyze the samples following the LP-44 kDamethod. Samples were prepared bymixing 5μl of proteinwith 10
μl of the saturated sinapic acid solution (molar ratio of sinapic acid to acetonitrile is 1:2, with added 0.1% (v/v)
of trifluoroacetic acid). Samples were loaded onto the plate and dried at room temperature. The spectrumwas
analyzed usingflexControl (Ultraflex) 3.0 software.Circular dichroism (CD) spectroscopy.TheAfb2C (0.5μg
ml−1)was analyzed in 20mMTris buffer at pH7.0 and pH11.0 using a CD spectrometer (Chirascan Plus
Spectroscopy). Samples were dialyzedwith the desired buffer at 4 °Covernight and the pHwas adjusted using 10
mMH2SO4.
Synthesis of Afb2C-PbSQDs
Afb2C in 70% (v/v) (NH4)2SO4was pelleted andwashedwith Tris buffer (20mMTris pH8.3) including 70%
(v/v) (NH4)2SO4 and pelleted again to remove theDTT. The pellet was dissolved in 1.7ml of 0.0167Maqueous
solution of lead acetate trihydrate (Pb(CH3CO2)2.3H2O) (Sigma), and 1.7ml of Tris buffer (40mMTris pH8.3)
was added. The pHwas adjusted to 11.0 using 0.1MNaOH. The reactionmixture was stirred for 30 min under
N2. Then 0.25ml of 0.1MNa2Swas added to the reactionmixture. The color of the solution changed to dark
brown indicating the formation of PbSQDs. TheAfb2C-PbSQDs solutionwas stirred for 30 min. Finally, the
product was dialyzed against Tris buffer (20mMTris pH11.0) overnight to remove excess reactants. TheQD
solutionswere stored under a nitrogen atmosphere at 4 °C in the dark.
Labelling of Afb2C-PbSQDswith ZnPP
Afb2C-PbSQDswere dialyzed against PB (20mMNaH2PO4 pH11.0) overnight at 4 °C. ZnPP labellingwas
performedmodified Thermo Scientific protocol. To produce the activated protoporphyrin-N-
hydroxysuccinimide ester (ZnPP-NHS), 100μl of ZnPP inDMSO (30mM)weremixedwith 12μl of 500mMof
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) inMES buffer (0.1MMES (2-[N-
morpholino]ethanesulfonic acid) pH6). The reactionmixture was agitated at room temperature for 1 min.
Following incubation, 12μl ofN-hydroxysuccinimide (NHS) (500mM) inMES buffer was added. The reaction
mixturewas agitated for further 15 min at room temperature before the solutionwas centrifuged at room
temperature (4000 g, 15 min) and any precipitates were discarded. Afb2C-PbSQDsweremixedwith a 10-fold
excess of the activated ZnPP-NHS ester under ambient conditions. The reactionmixturewas protected from
light andwas gently agitated overnight at room temperature. The product was centrifuged at 5000 g for 10 min to
remove unreacted protoporphyrin and then dialyzed against PB (20mMNaH2PO4 pH8.3) overnight at 4 °C.
TheQD solutionswere stored under a nitrogen atmosphere at 4 °C in the dark.
Optical andmorphological characterization
The PL of PbSQDswas analyzed using aHoriba Jobin Yuon LtdHR800 LabRam setup equipped in InGaAs
detector. The excitationwas providedwith aHe-Ne laser (λ=633 nm,P=104Wcm−2). For transmission
electronmicroscopy (TEM) studies, PbSQDs at a concentration of 0.1mgml−1 were deposited on a graphene-
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oxide-coatedCu grid (Agar Scientific) andTEM images were recorded on the JEOL2100EXmicroscope
operating at 120 keV.
In vitro studies
SKBR3 andMDA-MB-231 breast cancer cell lines were cultured under optimumconditions in RPMI nutrient
medium (Sigma-Aldrich) supplementedwith 10% fetal bovine serum (FBS; SigmaAldrich), and sub-cultivated
twiceweekly tomaintain logarithmic growth. ForMTT assays, cells were seeded into 96-well plates at a density
of approximately 3×103 cells/well in 180μlmedium and allowed to adhere to the plates by incubating at 37 ˚C
for 24 h. Serial dilution of Afb2C-PbSQDs or ZnPP-Afb2C-PbSQDswere prepared and 20μl per well was
added to achieve afinal concentration of Afb2C from0.1μgml−1 to 120μgml−1. After 72 h exposure,MTT
solution (50μl 2mgml−1)was added to eachwell and incubated for 3 h. Themediumwas aspirated andDMSO
(150μl)was added to dissolve the formazan crystals. The absorbancewasmeasured at 550 nmusing an En
Vision 2104Multilabelmicroplate reader (PerkinElmer).
For cell cycle andAnnexinV assays, cells were seeded in a 6-well plate at a density of 7.5×104 cells/well in 2
ml of RPMI nutrientmedium supplementedwith 10%FBS, and allowed 24 h to adhere. The cells were treated
with 2xGI50 concentrations of Afb2C-PbSQDs andZnPP-Afb2C-PbSQDs for 24 h, 48 h and 72 h. The
medium, containing dead cells, was collected into labelledfluorescence activated cell sorter (FACS) tubes and
kept on ice. The remaining adherent cells were trypsinizedwith 500μl of 1× trypsin-EDTAbefore poolingwith
themedium containing dead cells. The cells were centrifuged at 4 °C (1200 rpm) for 5 min, the supernatant was
removed, and the cell pellets washedwith 1ml of PBS followed by another cycle of centrifugation. The
supernatant was decanted.
For cell cycle assays, cell pellets were resuspended in 500μl of cold hypotonic fluorochrome solution (50μg
ml−1 PI (Sigma-Aldrich), 0.1mgml−1 ribonuclease A (Sigma-Aldrich), 0.1% v/v TritonX-100 (Sigma-Aldrich),
0.1%w/v sodium citrate (Sigma-Aldrich) dissolved in PBS), protected from light and stored overnight at 4 °C.
Samples were vortexed and analyzed on a BeckmanCoulter Epics-XLMCLflow cytometer. At least 10 000
events were recorded for each sample. The results were analyzed using EXPO32 software.
For annexinV assays, the AnnexinV-FITC/PI (AV/PI) (BDPharmingen) kit was used. To FACS tubes
containing cell pellets, 400μl of 1× annexin binding buffer and 10μl of PI solutionwere added, samples were
vortexed and incubated for 10 min at room temperaturewithout light. Samples were analyzedwithin 1 h on a
BeckmanCoulter Epics-XLMCL flow cytometer and at least 10 000 events were recorded for each sample. The
results were analyzed using EXPO32 software.
The cellular uptake of ZnPP-Afb2C-PbSQDswas studied using flow cytometry. Cells were seeded at a
density of 7.5×104 cells/well in 6well plates in 2ml of RPMI nutrientmedium and allowed 24 h to adhere. The
cells were treatedwith 2×GI50 concentration of ZnPP-Afb2C-PbSQDs for 3 h. The cells were thenwashed (2-
times 2ml of PBS), trypsinized (0.5ml 0.25%w/v trypsin-EDTA), pooled (1ml RPMInutrientmedium) and
centrifuged for 5 min at 1200 g (BeckmanCoulter Allegro). The cell pellet was furtherwashed (2× 1ml PBS),
centrifuged and resuspended in 0.5ml of PBS. Astrios EQflow cytometer (BeckmanCoulter)with excitation at
λex=425 nmandKaluza FlowCytometry software were adopted for analysis .
Confocalmicroscopy
Cells were seeded in an 8-wellμ-slide confocal chamber (Ibidi GmbH,Munich, Germany) at a density of
7.5×104 per well. After overnight incubation, cells were treatedwith before treatment with 2×GI50 of ZnPP-
Afb2C-PbSQDs. After 24 h exposure, cells werewashed (3×0.2ml PBS),fixed (0.2ml 4% (v/v) formaldehyde,
20 min), thenwashed again (3×0.2ml PBS). Fixed cells were stainedwithDRAQ5™DNA stain, thenwashed
(3×0.2ml PBS). Confocalmicroscopy images were captured on LEICADMI 4000 Busing excitation
wavelengthsλex=425 nmandλem=593 nm. ImageJ (Fiji) software was used for image analysis.
Statistical analysis
For all experiments, n3 internal replicates and n3 independent trials were conducted. Data were analyzed
using one-way, two-way analyses of variance (ANOVAs), and t-tests; p<0.05 identified significance.
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